Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

Common

Stock

December 16	6, 2004											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION							OMB APPROVAL					
Washington, D.C. 20549							OMB Number:	3235-0287				
Check th if no long subject to Section 1 Form 4 o	ger o STATEM 16.	STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIES								Expires: Estimated a burden hou response		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type Responses)												
VAGELOS P ROY Symbol REG PHA			Symbol						5. Relationship of Reporting Person(s) to Issuer			
			REGENERON PHARMACEUTICALS INC [REGN]						(Check all applicable) _X_ Director 10% Owner			
(Last)			Earliest Transaction ny/Year)					Officer (give title below) Other (specify below)				
777 OLD SA ROAD	AW MILL RIVEI	R	12/15/20	004								
Filed(Mont				ndment, Date Original nth/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
TARRYTOWN, NY 10591 — Form fried by Mole than One Reporting Person												
(City)	(State)	(Zip)	Table	I - No	n-De	erivative S	ecurit	ies Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	Security (Month/Day/Year) Execution Date, if			3. 4. Securities Acquired Transaction(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5)				of	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
				Code	V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	06/25/2004			G <u>(1)</u>	V	20,870 (2)	D	\$0	551,715	I	by CLAT	
Common Stock	09/28/2004			G <u>(1)</u>	V	24,393 (2)	D	\$ 0	527,322	I	by CLAT	
Common Stock									851	D		

GRAT

by GRAT

245,682

200,000

Ι

I

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock

Common Stock 10,655 I by GRAT

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou Underlying Secur (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Am Nui Sha
Incentive Stock Option (right to buy)	\$ 9.49	12/15/2004		A	42,148	(3)	12/15/2014	Common Stock	42
Non-Qualified Stock Option (right to buy)	\$ 9.49	12/15/2004		A	270,352	(3)	12/15/2014	Common Stock	27

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
VAGELOS P ROY 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	X						

Signatures

**/s/P. Roy

Vagelos 12/16/2004

**Signature of Person Date

Reporting Person

Reporting Owners 2

Dolotionshin

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Gift of Common Stock to charitable organization.
- (2) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- (3) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.